This website uses cookies to ensure you get the best experience on our website.
Privacy Policy
I Agree
UroToday
Contact
Login
Sign Up Free
Transformative Evidence
mCRPC
The RALU Study: Treatment Considerations in the First Line Setting of mCRPC
PROfound
VISION Trial
mHSPC
ARASENS Trial
nmCRPC
ARAMIS Trial
nmCSPC
EMBARK Trial
PSMA PET Imaging
COBRA
CONDOR Trial
OSPREY Trial
Bladder Cancer
Bladder Cancer Detection
CORE-001
CS-003
Centers of Excellence
Urologic Oncology
Left Group
Health Policy
Health Policy
Ruchika Talwar, MD
Bladder Cancer
Bladder Cancer
Ashish Kamat, MD
Advanced Bladder Cancer
Shilpa Gupta, MD
Trimodality Therapy
Leslie Ballas, MD
Kidney Cancer
Advanced Kidney Cancer
Pedro Barata, MD, MSc
Endourology
Endourology
Jaime Landman, MD
Prostate Cancer
Decipher Genomic Classifier
Advanced Prostate Cancer
Zachary Klaassen, MD, MSc
CRPC with Bone Metastases
Rana R. McKay, MD
Imaging Center
Phillip Koo, MD
Localized Prostate Cancer
Matthew R. Cooperberg, MD, MPH
mHSPC
Neeraj Agarwal, FASCO, MD
nmCRPC
Zachary Klaassen, MD, MSc
PSMA-Targeted Therapy
Disparities: Social Determinants of Health
Disparities: Social Determinants of Health
Samuel L. Washington III, MD, MAS
Translational Prostate Cancer
Translational Science in Prostate Cancer
Andrea Miyahira, Ph.D
Women in Science
Andrea Miyahira, Ph.D
Upper Tract Urothelial Carcinoma
Upper Tract Urothelial Carcinoma
Sam S. Chang, MD, MBA
TESTICULAR, PENILE & RARE GU MALIGNANCIES
Testicular Cancer
Pelvic Health & Reconstruction
Bladder Health
Diane K. Newman, DNP, ANP-BC, FAAN
Pelvic Health
Diane K. Newman, DNP, ANP-BC, FAAN
Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU)
Stephen R. Kraus, MD
Urologic Catheters (Includes CAUTI)
Diane K. Newman, DNP, ANP-BC, FAAN
Videos
Exclusives
Conferences
Exclusive Collaborations
Independent Medical Education
Covid-19
The Prostate Cancer Foundation
Health Policy in Urological Diseases
Disparities: Social Determinants of Health
Practice Guidelines Reviews
Urologic Oncology
Prostate Cancer
Bladder Cancer
Kidney Cancer
Upper Tract Urothelial Tumors
Testicular Cancer
Endourology
Pelvic Health & Reconstruction
Pelvic Health & Reconstruction
Trials in Progress
Trials in Progress
Bladder Cancer
IMMORTAL
PIVOT-006
Kidney Cancer
RadiCal
SAMURAI
Middle Side
Prostate Cancer
ARAMON
ARASEC
ARASTEP
CLARIFY
ECLIPSE
ESCAPE
FORT
Right Side
Prostate Cancer
Masofaniten (EPI-7386)
METANOVA
NRG-GU 0101
PROMISE
RTIRE
SECuRE
SHORTER
Clinical Trials
From the Editor
Search Clinical Trials
Articles
Urology (benign and malignant)
Urologic Oncology
Men's Health
Endourology & Stones
Pediatric Urology
COVID-19 and Genitourinary Cancers
Pelvic Health
Pelvic Health & Reconstruction
Conference Coverage
Recent Conferences
WCET 2024
BCAN TT 2024
SNMMI 2024
ASCO 2024
AUA 2024
All Conferences
View All
PCF
UroToday Home
Conference Highlights
SUO 2023
SUO 2023
Prostate Cancer
Kidney Cancer
Bladder Cancer
Penile, Urethral, Testicular, and Adrenal Cancers
Upper Tract Urothelial Carcinoma
Press Releases
SUO 2023 Bladder Cancer
Viewing 1-12 of 12 articles
SUO 2023: Optimizing Care for Women: Gynecologic Considerations for the Urologic Oncologist
SUO 2023: Long-term Outcomes of Bladder-Sparing Therapy Compared to Upfront Radical Cystectomy in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer in an International Cohort
SUO 2023: Primary Chemoablation for Recurrent Low Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer: The ENVISION Trial
SUO 2023: First Results from BOND-003, a Phase 3 Study of Intravesical Cretostimogene Grenadenorepvec Monotherapy for Patients with High-Risk BCG Unresponsive NMIBC
SUO 2023: Treatment of Low-grade, Intermediate-risk Non-muscle Invasive Bladder Cancer with UGN-102 ± Transurethral Resection of Bladder Tumor (TURBT) compared to TURBT Monotherapy: The Phase 3 ATLAS Trial
SUO 2023: Marker Lesion Study of Oral Erdafitinib in Patients With Intermediate-Risk Non–Muscle-Invasive Bladder Cancer With FGFR3/2 Alterations in THOR-2: Updated Cohort 3 Results
SUO 2023: Comparing White Light versus Blue Light Cystoscopy Recurrence Outcomes Among Non-Muscle Invasive Bladder Cancer Patients in an Equal Access Setting: A Propensity-scored Matched Analysis
SUO 2023: Efficacy of Intravesical Nadofaragene Firadenovec-vcng for Patients with Bacillus Calmette-Guerin-Unresponsive Carcinoma in Situ of the Bladder: 36-Month Follow-Up from a Phase 3 Trial
SUO 2023: Updated Efficacy and Safety of Oral Erdafitinib in Patients With Bacillus Calmette–Guérin-Unresponsive, High-Risk, Non–Muscle-Invasive Bladder Cancer With FGFR3/2 Alterations in THOR-2 Cohort 2
SUO 2023: Bladder Cancer Debate for MIBC: Trimodality Therapy/Radiotherapy after Complete Clinical Response
SUO 2023: Bladder Cancer Debate for MIBC: Neoadjuvant Chemotherapy Followed by Surveillance if Complete Clinical Response
SUO 2023: Bladder Cancer Debate for MIBC: Radical Cystectomy SHOULD be Performed after Achieving cT0 after Neoadjuvant Chemotherapy
×
Login
Login to update email address, newsletter preferences and use bookmarks.
Email
Password
Login
Forgot Password?
Sign Up Free